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Myogenic differentiation in the C2C12 myoblast model system reﬂects a concerted and controlled activation of
transcription and translation following the exit of cells from the cell cycle. Previously we have shown that the mTORC1
signaling inhibitor, RAD001, decreased protein synthesis rates, delayed C2C12 myoblast differentiation, decreased
p70S6K activity but did not affect the hypermodiﬁcation of 4E-BP1. Here we have further investigated the modiﬁcation
of 4E-BP1 during the early phase of differentiation as cells exit the cell cycle, using inhibitors to target mTOR kinase and
siRNAs to ablate the expression of raptor and rictor. As predicted, inhibition of mTOR kinase activity prevented p70S6K,
4E-BP1 phosphorylation and was associated with an inhibition of myogenic differentiation. Surprisingly, extensive
depletion of raptor did not affect p70S6K or 4E-BP1 phosphorylation, but promoted an increase in mTORC2 activity (as
evidenced by increased Akt Ser473 phosphorylation). These data suggest that an mTOR kinase-dependent, but raptor-
independent regulation of downstream signaling is important for myogenic differentiation.
Introduction
The differentiation of skeletal muscle cells involves the exit of
mononucleated myoblasts from the cell cycle, changes in activity
of an array of signaling pathways, altered gene expression, and
cell fusion to form multinucleated myotubes.1,2 It is likely that
this process reflects the induction of IGF-II3,4 which signals via
the Insulin-like growth factor 1 (IGF-1) receptor to activate phos-
phatidylinositol-3 kinase (PI3-K), protein kinase B (Akt), the
Tuberous Sclerosis Complex (TSC1/2), and mammalian target of
rapamycin (mTORC1) signaling.5-7 Activation of mTORC1 and
phosphorylation of its downstream targets are central to the
control of protein synthesis in many cell types, but the role of
mTOR activity and its downstream signaling pathways in regulat-
ing differentiation in C2C12 myoblasts remains unclear.8-13
mTOR is contained within 2 distinct complexes: mTORC1
and mTORC2.13-15 The former complex includes mTOR, rap-
tor, mLST8, proline-rich Akt substrate 40 kDa (PRAS40), DEP-
domain-containing partner of mTOR (DEPTOR), and scaffolds
tti1/tel27,13,16 mTORC1 regulates the phosphorylation and
activity of eIF4E-binding proteins (4E-BP15,7,14) and the ribo-
somal protein S6 kinase, p70S6K.17 mTORC2, a complex
including mTOR, rictor, protor1/2, DEPTOR, mLST8, and
scaffolds tti1/tel2/mSin1 (reviewed in7), is known to regulate
Akt, protein kinase Ca and serum-and glucocorticoid-induced
protein kinase 1.18-20 In addition, mTORC2 plays an important
role in regulating the actin cytoskeleton.21 Down-regulation of
rictor has been reported to inhibit the ability of mTORC2 to
phosphorylate Akt on Ser473 and stimulates protein synthesis in
C2C12 myocytes.12
Protein synthesis is carried out in 3 stages (initiation, elongation
and termination), with the initiation stage of translation generally
accepted as a major site of regulation of gene expression in mamma-
lian cells.5,7,22-30 This step in protein synthesis is regulated by a fam-
ily of proteins, the initiation factors5,23,24 which interact with each
other and the mRNA. These proteins modulate the binding of
mRNA to the ribosome, a process facilitated by the assembly of the
cap binding protein, eIF4E, a helicase, eIF4A, and a scaffold protein,
eIF4G, into the eIF4F complex (eIF4E/eIF4A/eIF4G). The control
of assembly of this complex is often dysregulated in tumor cells.5-
7,13,17,23 The eIF4G scaffold protein possesses domains that interact
with eIF4E, eIF4A, the multi-factor protein, eIF3, poly(A) binding
protein (PABP) and the kinases,Mnk1/2, whichmodulate the phos-
phorylation of eIF4E on Ser209.5,14,17,22–25
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The activity of the eIF4F complex is regulated its assembly,
phosphorylation of components and the inherent structural
properties of the recruited mRNA.5,17,23-25 Using a conserved
motif, 4E-BP1 competes with eIF4G for a common surface on
eIF4E and inhibits eIF4F assembly. Activation of mTORC1
leads to the multi-site phosphorylation of 4E-BP14,15 and the
recruitment of mTORC1 to eIF3 resulting in p70S6K activa-
tion.17,25 The former prevents 4E-BP1 from binding to eIF4E
and thereby allows formation of the eIF4F initiation complex
and ribosomal recruitment of mRNA.22-24
Previously, we have shown that myogenic differentiation is
associated with increased rates of translation, biphasic activation
of p70S6K, and the phosphorylation of both eIF4E and 4E-
BP1.26 Paradoxically, treatment of C2C12 myoblasts with an
inhibitor of mTORC1 (RAD00127), delayed differentiation but
led to the hypermodification of 4E-BP1 and to enhanced levels of
initiation factor 4E (eIF4E)/4E-BP1 complex.26 Here we further
investigate the signaling pathways responsible for the modification
of 4E-BP1 during exit from the cell cycle using inhibitors of
mTOR kinase and siRNAs to ablate expression of raptor and ric-
tor. We show that as cells exit the cell cycle, depletion of raptor
does not affect p70S6K or 4E-BP1 phosphorylation, but pro-
moted an increase in mTORC2 activity (as evidenced by
increased Akt Ser473 phosphorylation). mTOR activity is
required for activation of p70S6K during myogenic differentiation
but 4E-BP1 phosphorylation is insensitive to depletion of either
raptor or rictor. These data suggest that an mTOR kinase-depen-
dent, but raptor-independent regulation of downstream signaling
is important for myogenic differentiation in mouse myoblasts.
Results
RAD001 inhibits p70S6K but maintains the phosphorylation
of 4E-BP1 during myogenic differentiation
We and others have previously shown that rapamycin10,12 or
RAD00126 potently inhibits myogenic differentiation in the
C2C12 myoblast model system. Furthermore, we showed that
although inhibition of mTORC1 reduced p70S6K activity, pre-
vented the phosphorylation of rpS6, reduced protein synthesis
rates and delayed myotube formation, paradoxically 4E-BP1
remained in a hyperphosphorylated form.26 To examine this fur-
ther we have explored the phosphorylation of 4E-BP1 in more
detail and compared the effects of RAD001 with kinase inhibitors
of mTOR, such as Torin 113 and KU0063794,31 and downstream
signaling following ablation of rictor or raptor using siRNA.
Figure 1A shows that even when used at 1 mM levels for
24 hours, RAD001 did not totally prevent the phosphorylation
of 4E-BP1 on Thr37/46, Ser65 or Thr70 (lane 6 vs. lanes 2–5).
In contrast, relative to untreated cells (lanes 1 and 2), RAD001
even at 50 nM levels inhibited the phosphorylation of p70S6K
and rpS6 (lane 3). To see if this was also true for other mTORC
inhibitors, we used KU0063794 which inhibits the kinase activ-
ity of mTOR.31 Figure 1A shows that KU0063794 inhibits the
phosphorylation of 4E-BP1 on Ser65, p70S6K and rpS6, while
reducing the phosphoryation of Ser70 and Thr37/46 (lane 7 vs.
lane 2). A partial decrease in 4E-BP1 phosphorylation was also
seen when cells were induced to differentiate in the presence of
the phosphatidylinositol 3-kinase (PI3-K) inhibitor, LY294002
(Fig. 1B). Under these conditions, LY294002 potently inhibited
myogenic differentiation and
eventually induced apoptosis in
C2C12 myoblasts (data not
shown).
Western blotting with phos-
pho-specific antisera strongly
suggests that even in the pres-
ence of RAD001, the phos-
phorylation of 4E-BP1 was
maintained during differentia-
tion. To address this more
directly, we have used extracts
prepared from cells incubated
in the absence or presence of
RAD001 or KU0063794 for 24
or 48 hours and subjected them
to lambda phosphatase treat-
ment. Figure S1 shows that in
differentiated cell extracts, this
phosphatase was effective
within 10 minutes, removing
modification on Ser 65 more
efficiently than Thr70 (lane
3 vs. lanes 2 and 1); Thr37/46
remained resistant to dephos-
phorylation (lanes 4–6) under
these assay conditions. Similar
Figure 1. RAD001 inhibits p70S6K but maintains the phosphorylation of 4E-BP1 during myogenic differentia-
tion. (A) C2C12 cells were grown to conﬂuency and induced to differentiate by serum withdrawal in the pres-
ence of 2% (v/v) horse serum, 10 mg/ml insulin and 10 mg/ml transferrin (DM). Cells were harvested
immediately (lane 1) or incubated for 24 hours in the absence (lanes 2) or presence of the indicated concen-
tration of RAD001 (lanes 3–6) or 10 mM KU0063794 (lane 7). Extracts were prepared as described in Materials
and Methods and aliquots containing 10 mg total protein resolved by SDS-PAGE and proteins visualized by
Western blotting using the antisera shown. (B) Cells were incubated as above but in the absence or presence
of 10 mM LY294002. Extracts were prepared as described in Materials and Methods and aliquots containing
10 mg total protein resolved by SDS-PAGE and proteins visualized by Western blotting using the antisera
shown. In both cases, results are shown from a single experiment but similar data were obtained in at least 3
independent experiments.
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results were seen with extracts from cells allowed to differentiate
in the presence of RAD001 (lanes 8–13). Figure 2A shows that
lambda phosphatase was able to dephosphorylate 4E-BP1 in
extracts prepared at 48 hours (Fig. 2A, lanes 2 and 5 vs. lanes 1
and 4), in a process prevented by NaF (lanes 3 and 6 vs, lanes 2
and 5). 4E-BP1 was dephosphorylated in cells incubated with
KU0063794, (lanes 7–9) and was not affected further by the
purified phosphatase. Further analysis showed that KU0063794
treatment of cells reduced the phosphorylation of Thr37/46,
Ser65 and Thr70 (Fig. 2B). In extracts prepared in the absence
or presence of RAD001, 4E-BP1 phosphorylation of Thr37/46
remained resistant to lambda phosphatase treatment. These data
confirm that the modification of 4E-BP1 observed during differ-
entiation represents discrete phosphorylation.
The ATM inhibitor, KU55399, does not affect
phosphorylation of 4E-BP1 during myogenic differentiation
The work described above shows that the PI3-kinase inhibi-
tor, LY294002, could partially inhibit phosphorylation of 4E-
BP1 in C2C12 cells, similar to that seen with RAD001.
Published work has suggested that insulin-induced phosphoryla-
tion of 4E-BP1 on Ser111 occurs in an Ataxia-Telangiectasia
Mutated kinase (ATM)-dependent manner.32 To address
whether ATM has a role in the RAD001-resistant phosphoryla-
tion of 4E-BP1 during differentiation of C2C12 myoblasts, we
have used an inhibitor of ATM, KU55933.33,34 Figure 3A shows
that KU55933 has no effect on the biphasic activation of
p70S6K (as monitored by phosphorylation at Thr389) or the
phosphorylation of Akt at Thr308. However, KU55933 was able
to reduce Akt Ser473 phosphorylation at later times suggesting
an inhibition of mTORC2 (lanes 7 and 8 vs. lanes 3 and 4). We
have also directly compared the effects of inhibition of ATM on
the phosphorylation of 4E-BP1 with those of RAD001, Torin 1
and KU0063794; unfortunately, no phospho-specific serum
exists for the Ser111 site. Figure 3B shows that incubation of cells
with KU55933 has a similar effect on 4E-BP1 phosphorylation
as seen with RAD001 (lane 6 vs. lane 3). Addition of both
KU55933 and RAD001 to cells did not further influence 4E-
BP1 phosphorylation (lane 7 vs. lanes 6 and 3). RAD001 did
however promote the phosphorylation of Akt Thr308 and reduce
phosphorylation at Ser473. These findings are consistent with
published data,35-37 possibly reflecting loss of inhibition of feed-
back signaling to IRS1 from p70S6K37 and inhibition of
mTORC2.35,36 In contrast, both Torin 1 (lane 4) and
KU0063794 (lane 5) completely inhibited 4E-BP1 and Akt
phosphorylation at 24 hours incubation.
Phosphorylation of 4E-BP1 is unaffected by siRNA-
mediated depletion of raptor or rictor
To further examine the role for mTOR in the regulation of dif-
ferentiation in C2C12 cells, we have ablated the expression of rap-
tor and/or rictor by >95% using siRNAs (see Materials and
Methods). After transfection, cells were harvested at different times
and the level of raptor and rictor mRNA and protein depletion
analyzed using qRT-PCR and Western blotting, respectively
(Figs. S2A and B). Consistent with published data,11,12 depletion
of raptor delayed, but did not prevent myogenic differentiation
while depletion of rictor had little effect or slightly stimulated the
process (data not shown) Figures S2A and B show that, relative to
untreated cells, mRNA and protein for both raptor and rictor
were depleted by >95% within 48 hours of transfection. In subse-
quent experiments, cells were incubated for 96 hours to allow for
48 hours in differentiation medium before extracts were prepared.
SDS-PAGE analysis of extracts showed that depletion of raptor
provoked an increase in the phosphorylation of Akt Ser473
(Fig. 4A, lane 7 vs, lanes 5 and 6) and to a lesser extent,
AktThr308 (Fig. 4B, lane 3 vs lane 2). This was not evident at
24 hours (Fig. 4A, lanes 3 and vs, lanes 1 and 2) or following
depletion of rictor at either time (lanes 4 and 8 vs. lanes 3 and 7).
However, although depletion of rictor did not affect 4E-BP1 or
Akt Ser473 phosphorylation, it did cause a reduction in Akt
Thr308 phosphorylation at later times (Fig. 4B, lane 4 vs lane 2).
Surprisingly, 4E-BP1 phosphorylation was unaffected by extensive
raptor protein depletion at any time analyzed (Figs. 4A and B).
Figure 2. Phosphorylation of 4E-BP1 from RAD001-treated cells is sensi-
tive to lambda phosphatase in vitro. (A) Cells were grown to conﬂuency
and induced to differentiate by serum withdrawal for 48 hours as in Fig-
ure 1, in the absence (control; lanes 1–3) or presence of 100 nM RAD001
(lanes 4–6) or 10 mM KU0063794 (lanes 7–9). Cell extracts were prepared
and aliquots containing 90 mg total protein incubated with 200 units of
lambda phosphatase for the times shown in the absence (lanes
1,2,4,5,7,8) or presence of 50 mM NaF (lanes 3,6,9) as described in Materi-
als and Methods. Aliquots containing 10 mg total protein were resolved
by SDS-PAGE and total 4E-BP1 protein visualized by Western blotting.
(B) Cells were incubated as described above. Extracts were prepared and
treated with lambda phosphatase as described in Panel A prior to SDS-
PAGE and Western blotting using the antisera shown. Results are shown
from a single experiment but similar data were obtained in at least 3
independent experiments.
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To investigate this further, cells were incubated with a scram-
bled siRNA or depleted of either raptor, rictor or both proteins
for 24 hours and cells subsequently allowed to differentiate for
48 hours in the absence or presence of KU0063794 (Fig. 5).
Here we show that following depletion of raptor with siRNA
(lane 3 vs lanes 2 and 12), there was no effect on p70S6K or
rpS6 phosphorylation at 48 hours of differentiation. Similar
findings were reported by Shu and Houghton (2009) who
depleted C2C12 cells using lentivirus vectors.12 Depletion of
raptor resulted in an increase in phosphorylation of Akt Ser473;
this could not be attributed to activation of p38MAPK (Fig. 5).
Again depletion of raptor had no effect on 4E-BP1 phosphoryla-
tion under these conditions. However, although the addition of
KU0063794 decreased the efficiency of siRNA-mediated raptor
depletion (lane 4 vs., lanes 3 and 2), it did prevent p70S6K acti-
vation, rpS6, 4E-BP1 and Akt Ser473 phosphorylation (lanes 4
and 13 vs, lane 3). Depletion of rictor using siRNA (lane 5 vs
lanes 2 and 12) had no effect on p70S6K activity, S6
phosphorylation, Akt Ser473 phosphorylation or p38MAPK
activity. Again there were no effects on 4E-BP1 phosphorylation
but incubation of cells in the presence of KU0063794 resulted in
inhibition of p70S6K, S6 phosphorylation, 4E-BP1 phosphory-
lation and Akt Ser473 (lanes 6 and 13 vs, lane 5). Depletion of
both raptor and rictor (lane 7 vs. lanes 2 and 14) showed effects
similar to depletion of rictor alone.
Considering that the mTORC1 complex is known to control
4E-BP1 phosphorylation during the upregulation of growth in a
number of cell systems, we were somewhat surprised to find that
extensive depletion of raptor had no effect on the KU0063794-
sensitive phosphorylation of 4E-BP1 in C2C12 cells. Therefore,
we used the same siRNAs to ablate raptor expression in murine
NIH3T3 cells to see whether effects were cell-specific. Figures S3A
and B show that ablation of either raptor or rictor did not affect
total levels of 4E-BP1 in growing cells or in cells starved and then
refed with 20% serum for 30 minutes. In contrast to C2C12
cells, decreased expression of raptor in NIH3T3 cells did not pro-
voke an increase in the phosphorylation of Akt Ser473
(Fig. S3B), but rather increased Akt Thr308 phosphorylation,
probably reflecting loss of inhibition of feedback signaling to
IRS1 from p70S6K.37 In serum-starved cells, depletion of raptor
(Fig. S3A, lane 9 vs lane 6) led to decreased AktThr308 and
p70S6K phosphorylation, and partial inhibition of ERK phos-
phorylation. However, depletion of raptor seemed to protect 4E-
BP1 phosphorylation from the effects of serum starvation. On
the addition of serum there was an increase in ERK and total 4E-
BP1 phosphorylation; consistent with published findings,17-19
raptor depletion prevented activation of p70S6K in NIH 3T3
cells (Fig. S3A, lane 12 vs. lane 9). To determine whether ERK
activity was responsible for 4E-BP1 phosphorylation here, we
repeated experiments in the absence or presence of PD184352, a
characterized inhibitor of ERK.38 As shown in Figure S3C, inhi-
bition of ERK did not prevent phosphorylation of 4E-BP1 in
refed cells, either in the presence or absence of raptor. Ablation
of rictor (lane 10 vs lane 6) led to increased p70S6K activity pos-
sibly reflecting increased expression of raptor.
Discussion
The differentiation of skeletal muscle cells involves their exit
from the cells cycle, changes in activity of an array of signaling
pathways, altered gene expression, and cell fusion to form multi-
nucleated myotubes.1,2 Previous work has shown a role for
mTOR in this response9-12,26 but the role of 4E-BP1 phosphory-
lation remains elusive. Current models suggest that hyper-
phosphorylated 4E-BP1 is released from eIF4E to allow for
cap-dependent translation.5,14 During myogenic differentiation,
this would promote the regulated recruitment of specific mRNAs
into active eIF4F complexes, disassembly of stored mRNA from
granules and the release of small, inhibitory RNAs (miRs) which
prevent translation of the associated mRNAs.5,17,22-25
In the present study we show that myogenic differentiation
promotes the hyperphosphorylation of 4E-BP1 and activation of
p70S6K in C2C12 cells. Similar findings with 4E-BP1 have been
Figure 3. The ATM inhibitor, KU55399, does not affect phosphorylation
of 4E-BP1. (A) Cells were grown to conﬂuency and induced to differenti-
ate by serum withdrawal for the times indicated in the absence (lanes 1–
5) or presence of 10 mM KU55399 (lanes 6–8). Extracts were prepared as
described in Materials and Methods and aliquots containing 10 mg total
protein resolved by SDS-PAGE and proteins visualized by Western blot-
ting using the antisera shown. (B) Cells were induced to differentiate by
serum withdrawal for 0 (lane 1), 4 (lane 2) or 24 hours (lanes 3–7) in the
absence (lanes 1,2) or presence of 100 nM RAD001 (lane 3), 100 nM Torin
1 (lane 4), 10 mM KU0063794 (lane 5), 10 mM KU55399 (lane 6) or 10 mM
KU55399 and 100 nM RAD001 (lane 7). Aliquots containing 10 mg total
protein were resolved by SDS-PAGE and proteins visualized by Western
blotting using the antisera shown.
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reported for human megakaryo-
cyte cells undergoing differentia-
tion.39 Figure 1 shows that
inhibition of mTORC1 with
RAD001 inhibited the phosphor-
ylation of p70S6K and rpS6 and
delayed differentiation (data not
shown), but did not totally pre-
vent the phosphorylation of 4E-
BP1 on Thr37/46, Ser65 or
Thr70. Phosphorylation of 4E-
BP1 was prevented by
KU0063794, a kinase inhibitor
of mTORC1, similar to reports
in HEK293 cells.40 We con-
firmed that 4E-BP1 modification
recovered in extracts from
RAD001-treated cells reflected
protein phosphorylation as this
was sensitive to lambda phospha-
tase in vitro (Fig. 2 and Fig. S1).
The nature of the RAD001-
resistant kinase responsible for
4E-BP1 phosphorylation here is
unknown. However, one poten-
tial candidate is the Ataxia-
Telangiectasia Mutated kinase, ATM.32 ATM kinase belongs to
the PI3-kinase superfamily and cross-inhibition within this fam-
ily is a common problem when using kinase inhibitors.33 In myo-
tubes with shRNA-mediated ATM knockdown, cells showed
decreased levels of Insulin-like growth factor 1-mediated phos-
phorylation of Akt Ser473, Akt Thr308 and p70S6 kinase activ-
ity.41 In addition, KU5593332,33 has been shown to prevent the
stimulation of p70S6K phosphorylation in C2C12 myotubes
exposed to IGF-1. To determine any potential role for ATM in
the maintenance of 4E-BP1 phosphorylation when mTORC1
was inhibited, we used KU55933.32,33 Figure 3 shows that ATM
was not involved in the phosphorylation of 4E-BP1 during dif-
ferentiation. Furthermore, as the PI3-K, Vps34, has been identi-
fied as a direct target of KU55933, our study also suggests that
this PI3-K plays no role in controlling mTORC1 during myo-
genic differentiation.34 The Pim family kinases have also been
shown to function in a rapamycin-insensitive way to mediate the
phosphorylation of 4E-BP1 in AML cells.42 To investigate
whether Pim kinases have a role in 4E-BP1 phosphorylation in
C2C12 cells, we used the Pim kinase inhibitor, SGI-1776.42,43
In C2C12 cells, SGI-1776 had no effect of myogenic differentia-
tion or the phosphorylation of 4E-BP1 (data not shown).
As KU0063794 has the ability to inhibit mTORC1,
mTORC2, phosphorylation of 4E-BP1, p70S6K, rpS6, protein
synthesis and differentiation, we explored mTORC signaling fur-
ther using siRNA-mediated ablation of raptor or rictor to specifi-
cally target these signaling nodes.16,18-20
Figures 4 and S2 show that depletion of raptor was effective in
these cells, it allowed cell fusion but delayed differentiation (data
not shown). Relative to untreated cells, >95% depletion of
raptor provoked an increase in the phosphorylation of Akt
Ser473 (Fig. 4A) with no effect on 4E-BP1 phosphorylation
(Fig. 5). Previous work has shown that during cells proliferation,
disruption of raptor prevented mTORC1 signaling to p70S6K
and 4E-BP1.16,18 Furthermore, skeletal muscle-specific ablation
of raptor, but not rictor resulted in muscle dystrophy.52
mTORC1 disruption using raptor siRNA or RAD001 also failed
to inhibit 4E-BP1 phosphorylation in AML cells.43 In megakar-
yopoiesis, the mTOR/rictor complex affects megakaryopoiesis by
regulating nuclear division and subsequent cell cycle progression,
whereas raptor signaling protects cells from autophagic cell
death.44 Published work suggests that downregulation of rictor
in C2C12 cells can inhibit mTORC2 signaling without inhibit-
ing mTORC1; this prevented phosphorylation of Akt on Ser473
and stimulated protein synthesis.12 Our data show that extensive
depletion of raptor had no effect on p70S6K or rpS6 phosphory-
lation during myogenic differentiation. However, phosphoryla-
tion of these proteins was still sensitive to the mTORC1/2
inhibitor, KU0063794. PRAS40 is unlikely have a role here as
depletion of PRAS40 does not alter the phosphorylation of 4E-
BP1 or p70S6K in either myoblasts or myotubes.45,46 As pre-
dicted, depletion of rictor by >95% had no effect on p70S6K,
rpS6 or 4E-BP1 phosphorylation; depletion of both raptor and
rictor showed effects similar to depletion of rictor alone. It seems
very unlikely that the residual level of available raptor or rictor
was sufficient to allow mTORC1/2 signaling toward 4E-BP1.
SW620 colorectal cancer cells also show resistance to mTORC1-
inhibiton with T37/46 phosphorylation of 4E-BP1 maintained
in the presence of mTOR kinase inhibitors.47 As mTOR was cat-
alytically inhibited (as indicated by the attenuation of S6K1
Figure 4. Phosphorylation of Akt Ser473 is stimulated siRNA-mediated depletion of raptor. (A) C2C12 cells
were untransfected (lanes 1,5) or transfected with 9.4 nM Ambion Silencer pro-sequence siRNAs speciﬁc to
either raptor (lanes 3,7), rictor (lanes 4,8) or a scrambled control siRNA (lanes 2,6), as described in Materials
and Methods. After 24 hours, the medium was changed and cells were incubated in DM for the times indi-
cated. Extracts were prepared and aliquots containing 10 mg total protein were resolved by SDS-PAGE for
and proteins visualized by Western blotting using the antisera shown. (B) Cells were treated as described in
Panel A and incubated in DM for 48 hours. Extracts were prepared and aliquots containing 10 mg total pro-
tein were resolved by SDS-PAGE for and proteins visualized by Western blotting using the antisera shown.
Results are shown from a single experiment but similar data were obtained in at least 3 independent experi-
ments. Depletion of raptor was determined at 95% +/¡3% (S.D, n D 3).
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T389 and AKT S473 phosphorylation, the maintenance of 4E-
BP1 phosphorylation likely reflects an mTOR-independent
mechanism and not the disruption of the mTORC1 complex
which can occur when high concentrations of inhibitors are
used.48 The former is supported by the finding that raptor
siRNAs did not affect 4E-BP1 phosphorylation in SW620 cells
even though they effectively blocked S6K1 phosphorylation.47
Previous work has shown that the mTORC1 pathway is
required for both differentiation and hypertrophy of C2C12 cells
but p70S6K1 and 4E-BP1 are not required for the myogenic sig-
naling of mTOR.49 The authors suggested that an acute mTOR-
dependent signaling mechanism is essential for skeletal muscle
differentiation, with increased transcription of negative regulators
of mTORC1 such as PTEN, AMPKb, or TSC2 up-regulated
later during differentiation.50 However, we see no evidence for
changes in the level of TSC2 protein or activation of AMPK in
our study (data not shown).
mTORC1 may be focused on
modulating levels of autoph-
agy,7,13 while mTORC2 signal-
ing modulates the actin
cytoskeleton and the down-regu-
lation of the Rho associated
kinase (ROCK) required for
myogenesis.12 On the other
hand, the requirement for acute
mTOR signaling might reflect
regulated changes in mitochon-
drial biogenesis and function,
events required for myogene-
sis.51 Translation of a subset of
mRNAs encoding nuclear-
encoded, mitochondria-related
proteins has been shown to be
selectively suppressed following
ablation of mTORC1 but
not mTORC251; decreased
mTORC1 activity decreased
mitochondrial function and
ATP production. However,
in vivo work indicates that rap-
tor is critical in the longer term
for muscle function and pro-
longed survival52; ablation of
rictor had no affect on muscle
function or morphology.
The question remains as to
what links mTOR kinase with
muscle cell hypertrophy. One
possible link is eIF3; recent
work53 has suggested that a con-
served TOS motif in eIF3f
allows it to interact with the
mTOR/raptor complex, which
phosphorylates S6K117 and reg-
ulates downstream effectors of
mTOR and cap-dependent translation initiation.17,53 Ablation
of eIF3f in muscle cells prevented mTORC1 activity, phosphory-
lation of p70S6K1, rpS6, 4E-BP1 and myogenic differentiation.
However, our data suggest that raptor, which recruits proteins
with a TOS motif to mTOR kinase, is not required for the phos-
phorylation of p70S6K or 4E-BP1 in our cells, making this an
unlikely explanation in C2C12 cells. Recent work from the
Sonenberg group provides another possible explanation, which
also presumes a central role for eIF3. This recent study shows an
mTORC1-dependent interaction of PABP-interacting protein 1
(Paip1) with eIF3g,54 promoting rates of translation. The Paip1-
eIF3 interaction was impaired by rapamycin and a rapalog but
stimulated by p70S6K1. This work also showed that p70S6K1
interacts with, and phosphorylates eIF3f, leading the authors to
suggest that p70S6K1 phosphorylates eIF3 to stimulate the
Paip1-eIF3 interaction and promotes translation initiation.53,54
Figure 5. Phosphorylation of 4E-BP1 is unaffected by siRNA-mediated depletion of raptor or rictor in C2C12
cells. C2C12 cells were untransfected (lanes 1,2,9,10,11) or transfected with Ambion Silencer pro-sequence
siRNAs speciﬁc to either raptor (lanes 3,4), rictor (lanes 5,6), both rictor and raptor (lanes 7,8), or appropriate
scrambled control siRNAs (lanes 12–14), as indicated. After 24 hours, cells were either left in the original
medium (lanes 1,9) or the medium changed to DM (lanes 2–8 and lanes 10–14) for 48 hours, in the absence
(lanes 1–3, 5,7,9,10,12,14) or presence of 10 mM KU0063794 (lanes 4,6,8,11,13). Extracts were prepared and ali-
quots containing 10 mg total protein were resolved by SDS-PAGE for and proteins visualized by Western blot-
ting using the antisera shown. Results are shown from a single experiment but similar data were obtained in at
least 3 independent experiments. Depletion of raptor was determined at 95% +/¡3% (S.D, n D 3).
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Whether mTOR or p70S6K directly phosphorylates eIF3f in
C2C12 cells or the effects of ablation of eIF3f on differentiation
are unknown at this time.
Materials and Methods
Chemicals and biochemicals
Materials for tissue culture were from Invitrogen, fetal calf
serum was from Biosera, LY294002, microcystin LR and anti-
actin antibody were from Sigma. RAD00127 was a gift from
Novartis (Basel, Switzerland), Torin 1 was from the Sabatini
lab,13 and KU0063794 and KU55933 were from Tocris. Unless
otherwise stated, antisera to rictor, raptor, phospho-p70S6K
(T389), phospho-S6 (S240/244), phospho-ERK (T202/Y204),
phospho-p38MAPK (T180/Y182), phospho-Akt (T308 or
S473), total 4E-BP1, phospho-4E-BP1 (T36/T37, S65 or T70)
and antisera to total proteins were from Cell Signaling Technol-
ogy. Antisera specific to eIF4GI and PABP were generated in-
house.28-30 Immobilon PVDF was from GE Healthcare and
unless otherwise stated, all other chemicals were from Sigma.
Tissue culture
C2C12 cells, provided by the ECACC, were cultured in
10 cm plates in DMEM supplemented with 20% fetal calf serum
at 37C in a humidified atmosphere containing 5% CO2.
21
NIH3T3 cells (passage #12), were maintained in DMEM sup-
plemented with 20% fetal calf serum, as above. When required,
C2C12 myoblasts were grown to 100% confluence in complete
medium and induced to differentiate by serum withdrawal in
the presence of 2% (v/v) horse serum, 10 mg/ml insulin and
10 mg/ml transferrin (DM). The medium was changed every
24 hours and if required, fresh inhibitors were added.
Preparation of cell extracts
Following treatment, cells were isolated in a cooled centrifuge
and washed briefly with 0.5 ml ice-cold PBS containing 2 mM
benzamidine. Pellets were resuspended in 100 ml ice-cold Buffer
A (20 mM MOPS(KOH), pH 7.2, 20 mM sodium fluoride,
1 mMmicrocystin, 75 mM KCl, 2 mMMgCl2, 2 mM benzami-
dine, 2 mM Na3VO4, complete protease inhibitor mix (-EDTA;
Roche) and lysed by vortexing following the addition of 0.5% (v/v)
Igepal and 0.5% (v/v) deoxycholate. Cell debris was removed by
centrifugation in a microfuge for 5 min at 4C28-30; a Bradford
assay was used to determine protein content of extracts which were
then frozen in liquid N2.
Polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting
Samples containing equal amounts of protein were resolved by
PAGE (SDS-PAGE) and processed for Western blotting as
described previously.26,28-30 Briefly, membranes were blocked using
Tris-Buffered Saline (TBS)/0.5% (v/v) Tween containing 3% (w/v)
BSA for 1 hour and incubated with antisera diluted in the same
overnight at 4C. Following washing in TBS-Tween, membranes
were incubated with horseradish peroxidase-conjugated secondary
antibody and signals developed using ECL.28-30
Lambda phosphatase treatment of cell extracts
Aliquots of total cell extract (90 mg) were incubated with
200 units of lambda phosphatase (NEB) using the man-
ufacturer’s conditions and buffers, in a final volume of 100 ml, in
the presence of MnCl2. Incubations were carried out for the
times indicated, in the absence or presence of 50 mM NaF; ali-
quots containing 10 mg extract protein were then removed into
SDS-PAGE sample buffer and the phosphorylation of 4E-BP1
visualized by Western blotting.
siRNA treatment of C2C12 cells
C2C12 cells (5 £ 104) plated in 6 well plates were grown to
confluency and transfected with 9.4 nM Ambion Silencer pro-
sequence siRNAs (Life Technologies) specific to either murine
rictor, raptor or both together (or scrambled control) using Lipo-
fectamine mRNAi Max. After 24 hours, the medium was
changed to DMEM in the presence of 2% (v/v) horse serum,
10 mg/ml insulin and 10 mg/ml transferrin and cells incubated
for the times indicated in the figure legends.
siRNA treatment of NIH3T3 cells
Cells (1 £ 105) were plated in 6 well plates, grown for
24 hours and then transfected using Lipofectamine mRNAi Max
with 9.4 nM Ambion Silencer pro-sequence siRNAs and cells
were incubated for 48 hours before harvesting.
Quantitative RT-PCR
RNA was extracted from cell extracts using an RNA easy
mini-kit (Qiagen, UK) as per manufacturer’s instructions. RNA
concentration was then quantified using a Nanodrop and 1mg of
RNA was used for cDNA synthesis using the Promega ImpromII
kit. The SYBR real-time PCR system (Kapa Biosystems) was
used to quantify transcript abundance for genes of interest and
18S rRNA was used as a control. Template equivalent to 5 ng of
RNA in cDNA library per reaction was added to each 20 ml reac-
tion with a final primer concentration of 200 nM per reaction.
Crossing thresholds were determined using MxPro software
(Agilent), and fold-difference in RNA quantity was calculated
using the relative quantification method (2¡DDct).
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